Androgen Deprivation Monotherapy (ADT) is no longer considered standard of care for treating recurrent and advanced prostate cancer
Traditionally men diagnosed with recurrent or advanced prostate cancer have been given androgen deprivation therapy (hormone therapy). The Prostate Cancer Foundation’s Medical and Scientific Advisory Board chairman, Prof Shingai Mutambirwa explains why this is no longer considered to be adequate.
